Alkermes Alks underwent analysis by 6 analysts in the last quarter and revealed a spectrum of points of view from Bullish to Bearish.
The table below offers a short representation of their recent reviews, with the changing sentiments in the past 30 days and comparing these with previous months.
| Bullish | Somewhat bullish | Indifferent | Somewhat bearish | Bearish | |
|---|---|---|---|---|---|
| Total Reviews | 3 | 1 | 2 | 0 | 0 |
| Last 30d | 1 | 0 | 0 | 0 | 0 |
| 1m ago | 1 | 0 | 0 | 0 | 0 |
| 2M ago | 0 | 1 | 2 | 0 | 0 |
| 3M ago | 1 | 0 | 0 | 0 | 0 |
Analysts recently evaluated Alkermes and have provided 12 months of price objectives. The average goal is $ 42.17, accompanied by a high estimate of $ 52.00 and a low estimate of $ 33.00. If we observe an increase of 12.15%, the current average has risen compared to the previous average price target of $ 37.60.
Insight into the reviews of analysts: an extensive breakdown
The analysis of recent analyst actions sheds light on the perception of Alkermes by financial experts. The following summary presents important analysts, their recent evaluations and adjustments to assessments and price objectives.
| Analyst | Analistic | Take action | Judgement | Current price objective | Prior price objective |
|---|---|---|---|---|---|
| Absheni Verma | UBS | Increase | Buy | $ 42.00 | $ 33.00 |
| Ami Fadia | Needham | Announcement | Buy | $ 45.00 | – |
| Leonid Timashev | RBC Capital | Increase | Performing sector | $ 40.00 | $ 39.00 |
| Joel Beatty | Baird | Increase | Overtake | $ 41.00 | $ 38.00 |
| Absheni Verma | UBS | Reduced | Neutral | $ 33.00 | $ 38.00 |
| David Hoang | German bank | Increase | Buy | $ 52.00 | $ 40.00 |
Important insights:
- Taken action: Analysts respond to changing market dynamics and business performance and update their recommendations. Whether they ‘maintain’, ‘increase’ or ‘lower’ their attitude, it means their response to recent developments with regard to Alkermes. This provides insight into the perspectives of analysts on the current state of the company.
- Judgement: Analysts unravel qualitative evaluations for shares, ranging from ‘outperform’ to ‘underperform’. These reviews provide insight into expectations for the relative performance of Alkermes compared to the wider market.
- Price objectives: Analysts investigate the dynamics of price objectives and provide estimates for the future value of the shares of Alkermes. This research reveals shifts in the expectations of analysts over time.
Navigating through these analyst’s evaluations In addition to other financial indicators, you can contribute to a holistic concept of the status of Alkermes. Stay informed and make data -driven decisions with our review table.
Stay informed of the reviews of the Alkermes analysts.
Dive in the background of Alkermes
Alerkermes PLC is a fully integrated biotechnology company that applies its own technologies to researching, developing and commercializing pharmaceutical products designed for unfulfilled medical needs in therapeutic areas. The company uses various to develop and commercialize products and thereby gain access to technological, financial, marketing, production and other resources. Alkermes buy active drugs from third parties or receive them from his external licensees to formulate products using his technologies. It works in the US, which produces maximum income, Ireland and the rest of the world.
Most important indicators: the financial health of Alkermes
Market capitalization analysis: The market capitalization of the company is above the sector average, indicating that it is relatively larger compared to peers. This can suggest a higher level of investor confidence and market recognition.
Turnover growth: Alerkermes’ revenue growth has confronted with challenges. From March 31, 2025, the company has a fall in turnover of approximately -12.52%. This indicates a decrease in the top positions of the company. Compared to his colleagues in the industry, the company is lagging behind with a growth rate lower than the average among peers in the health care sector.
Net margin: The net margin of Alkermes surpasses industrial standards, which emphasizes the exceptional financial performance of the company. With an impressive 7.33% Netto margin, the company effectively manages the costs and achieves strong profitability.
Return on Equity (roe): The Roe van Alkermes surpasses the industry standards and emphasizes the exceptional financial performance of the company. With an impressive 1.51% Roe, the company makes effective use of shareholders share capital.
Return on assets (ROA): The Roa van Alkermes surpasses the industrial standards and emphasizes the exceptional financial performance of the company. With an impressive 1.09% Roa, the company effectively uses its assets for optimum returns.
Debt management: The company maintains a balanced debt approach with a debt-equity ratio under industrial standards, standing on 0.05.
Insight into the relevance of analyst reviews
Ratings come from analysts or specialists within bank and financial systems that report for specific shares or defined sectors (usually once every quarter for each shares). Analysts usually distract their information from business conferences and meetings, financial statements and conversations with important insiders to make their decisions.
Analysts can supplement their ratings with predictions for statistics such as growthms, income and income, so that investors offer more extensive prospects. However, investors must take into account that analysts, like every person, can have subjective perspectives that influence their predictions.
Which shares are analysts who now recommend?
Benzinga Edge gives you immediate access to all major analysts upgrades, downgrades and price goals. Sort on accuracy, upward potential and more. Click here to stay ahead of the market.
This article was generated by Benzinga’s automated content -engine and assessed by an editor.
#Alerkermes #Stock #deep #dive #analyst #perspectives #reviews #Alerkermes #Nasdaq #Alks